Last reviewed · How we verify
BIIX 1 XX - single rising dose
At a glance
| Generic name | BIIX 1 XX - single rising dose |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers (PHASE1)
- Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIIX 1 XX - single rising dose CI brief — competitive landscape report
- BIIX 1 XX - single rising dose updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI